MedPath

VARMAM THERAPY WITH AND WITHOUT KURUNTHOTTI KASHAYAM for the CEGANAVATHAM (CERVICAL SPONDYLOSIS)

Phase 3
Not yet recruiting
Conditions
Other spondylosis with radiculopathy,
Registration Number
CTRI/2020/11/029368
Lead Sponsor
National Institute of Siddha
Brief Summary

This is the comparative two arm clinical study to evaluate the efficacy of varmam therapy with and without kurunthotti kashayam in the management of ceganavatham in 40 patients for 48 days. The outcome will be measured by Universal pain scale and reduction in clinical symptoms.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Pain present behind the neck Region, aggravated by movement 2.
  • Neck stiffness 3.
  • Difficulty in flexion and extension of neck 4.pain radiating to shoulder blade, top of the shoulder, upper arm and back of the head 5.
  • Dizziness or vertigo 6.
  • Numbness in both upper limb 4.
  • Pain radiating to.
Exclusion Criteria
  • Patient with uncontrolled hypertension 2.pregancy and lactation 3.
  • Cervical rib 4.
  • Spina bifida 5.
  • Ankylosis spondylosis 6.
  • Rheumatoid arthritis 7.
  • Patient with thyroid 8.
  • Any trauma history 9.
  • Loss of bowel and bladder control 10.
  • Dysphagia 11.
  • Fracture in neck region 12.
  • Coronary artery disease 13.
  • Tuberculosis 14.
  • Severe osteoporosis 15.
  • Neck surgery.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
UNIVERSAL PAIN ASSESSMENT SCALE48 days
Secondary Outcome Measures
NameTimeMethod
To study the siddha basic principles relevant to the diseases48 days

Trial Locations

Locations (1)

Ayothidoss pandithar hospital

🇮🇳

Kancheepuram, TAMIL NADU, India

Ayothidoss pandithar hospital
🇮🇳Kancheepuram, TAMIL NADU, India
Dr D Krishnapriya
Principal investigator
8012634515
krishnadoss14@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.